THE OMIDRIA® EXPERIENCE

February 25, 2021

SPONSORED CONTENT

Surgical Case Series

Supported by Omeros Corporation:

Piecing together ways to improve the patient and surgeon experience during and after cataract surgery as demonstrated by leading experts!

If you would like a representative from Omeros to contact you about OMIDRIA, please click here

INDICATIONS AND USAGE

OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo®
are registered trademarks of Omeros Corporation.
© Omeros Corporation 2021, all rights reserved. US-OM-2000053